Published • loading... • Updated
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
The lawsuits allege weakening adoption and market share losses for Librela, Simparica Trio, Apoquel and Cytopoint, and investors face a July 27 lead-plaintiff deadline.
- On Thursday, Rosen Law Firm and Bronstein, Gewirtz & Grossman, LLC announced a securities class action lawsuit against Zoetis Inc. covering investors who purchased securities between January 14, 2025, and May 6, 2026.
- The lawsuit alleges Zoetis made misleading statements about sales growth and veterinarian adoption for its flagship Companion Animal products while failing to disclose that demand was actually weakening significantly.
- Clinicians became cautious regarding Librela following FDA safety warnings about neurological complications in dogs, while competitors undercut Simparica Trio and dermatology products Apoquel and Cytopoint, causing substantial market share losses.
- Investors who suffered losses must move the Court by July 27, 2026, to seek appointment as lead plaintiff, though participation in potential recovery does not require serving in this role.
- Bronstein, Gewirtz & Grossman represent investors on a contingency fee basis, with Founding Partner Peretz Bronstein stating the practice "centers on restoring investor capital and ensuring corporate accountability.
Insights by Ground AI
10 Articles
10 Articles
Coverage Details
Total News Sources10
Leaning Left0Leaning Right1Center7Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
12%
Factuality
To view factuality data please Upgrade to Premium
